Clinical Trial Update: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for recurrent high-grade glioma treated with APG-157 in combination with bevacizumab, currently recruiting in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Glioma

Drugs mentioned

• APG-157
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Aveta Biomics, Inc. | Conditions: Glioma, Glioblastoma Multiforme | Phase 1, Phase 2 | Status: RECRUITING